Cellanome vs DNAnexus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellanome is building a multi-omics platform combining genome sequencing, microfluidics, and integrated sensors to measure biological data at single-cell resolution; raised $100M Series A in 2023;
About
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.
About
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.